S&P Futures
3,785.75 -3.75 (-0.10%) Dow Futures
30,744.00 -37.00 (-0.12%) Nasdaq Futures
11,511.00 -18.50 (-0.16%) Russell 2000 Futures
1,706.10 -1.90 (-0.11%) Crude Oil
107.46 +1.70 (+1.61%) Gold
1,791.70 -15.60 (-0.86%)
AVROBIO, Inc. (AVRO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.0100 |
| Open | 0.9800 |
| Bid | 0.8000 x 800 |
| Ask | 0.0000 x 1000 |
| Day's Range | 0.9200 - 0.9996 |
| 52 Week Range | 0.7400 - 9.3700 |
| Volume | |
| Avg. Volume | 510,945 |
| Market Cap | 40.201M |
| Beta (5Y Monthly) | 1.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AVRO
Related Research
- AVROBIO, Inc.Daily – Vickers Top Buyers & Sellers for 07/09/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast yearArgus Research
- Business Wire
AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
CAMBRIDGE, Mass., May 18, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced preclinical data demonstrating the efficacy and safety of AVR-RD-03 gene therapy in a mouse model of infantile onset Pompe disease. The results, which will be presented today during the "Disease models and Clinical Applications: Musculo-skeletal Diseases" poster session at the American Society of Gene
- Business Wire
AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures
CAMBRIDGE, Mass., May 17, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported new interim data, including on new visual motor integration, motor coordination and visual perception measures, from a collaborator-sponsored, ongoing Phase 1/2 gene therapy clinical triali of AVR-RD-04, an investigational gene therapy for cystinosis, at the 25th Annual Meeting of American Society for G
- Business Wire
AVROBIO to Present at the H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass., May 16, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced members of its senior management team will be presenting virtually at the H.C. Wainwright Global Investment Conference, May 23-25, 2022.
